Cramer Backs Merck's Diversification Push, Sees Path Beyond Keytruda Reliance
CNBC's Jim Cramer has spotlighted Merck & Co. as a strategic holding, praising the pharmaceutical giant's acquisition-driven strategy to build a more balanced portfolio ahead of its blockbuster drug's patent cliff.